HGH Fragment 176-191

What is HGH Fragment 176-191?#

HGH Fragment 176-191 is a peptide that has been studied in preclinical and clinical research models for its potential therapeutic properties.

Mechanism of Action#

Introduction Human growth hormone (hGH) Fragment 176–191—often studied as the stabilized analog AOD9604—retains the lipolytic/antilipogenic functions attributed to the C‑terminus of hGH while lacking classical growth hormone receptor (GHR) activity. Below, we summarize receptor interactions, downstream signaling, molecular targets, and system-level effects supported by available evidence.

Receptor interactions

• Does not engage the canonical hGH receptor: Radioligand competition (125I‑hGH) shows no displacement by AOD9604/hGH177–191, and BaF3‑hGHR proliferation assays show no receptor-mediated growth signaling, indicating the fragment does not bind or activate GHR under tested conditions.
• Putative adrenergic interface: Several reports propose upregulation of β3‑adrenergic receptors (β3‑AR) in adipose tissue after AOD9604 exposure, consistent with enhanced sensitivity to catecholamine-driven lipolysis; however, the initiating receptor for AOD9604 itself remains unidentified and mechanistic authors highlight that the overall initiating mechanism is incompletely defined.

Downstream signaling pathways

• cAMP/PKA lipolytic axis (inferred): Upregulation of β3‑AR and increased lipolysis suggest activation of the cAMP–protein kinase A (PKA) cascade that phosphorylates and activates hormone‑sensitive lipase (HSL), although direct measurements of cAMP/PKA with AOD9604 are limited in the excerpts.
• DAG signaling: In vitro adipose studies show diacylglycerol (DAG) generation during AOD9401 exposure, indicating altered glycerolipid/FFA signaling and potentially facilitating lipolytic flux and re‑esterification dynamics.
• Antilipogenic signaling converging on ACC: Fragment exposure is associated with reduced acetyl‑CoA carboxylase (ACC) activity in adipose tissue (and reported in hepatocytes in broader context), consistent with decreased malonyl‑CoA and diminished de novo lipogenesis; this supports a shift toward fatty acid oxidation.
• Lack of classical GHR/JAK‑STAT: Absence of GHR binding/activation implies downstream JAK‑STAT signaling typical of hGH is not engaged by the fragment.

Molecular targets and cellular effects

• Hormone‑sensitive lipase (HSL): Increased activity and glycerol release in adipose tissue are consistent with HSL activation and net triglyceride hydrolysis.
• Acetyl‑CoA carboxylase (ACC): Directly or indirectly inhibited in adipocytes, reducing lipogenesis by ~43–57% in vitro; adipocyte size diminishes with chronic exposure, indicating cellular remodeling of lipid stores.
• Lipoprotein handling and FFA fate: Fragment treatment increases glycerol release and modifies FFA:glycerol ratios below 3:1 in vitro, implying partial oxidation or re‑esterification of liberated fatty acids; these dynamics align with elevated fat oxidation observed in vivo.

System-level physiology and extra‑adipose actions

• Net fat oxidation and adiposity: In obese mice, AOD9604 markedly increases fat oxidation (~2‑ to 3‑fold in reports) and reduces adiposity/weight gain, with concomitant increases in circulating glycerol/FFA that indicate enhanced lipid mobilization.
• Glycemic neutrality relative to hGH: Unlike full‑length hGH, the fragment does not induce hyperglycemia or insulin resistance in the conditions tested; glucose and insulin were largely unchanged in treated models, and clamp studies did not reveal glucose intolerance in related work.
• Hepatic contribution (contextual): ACC inhibition has been described in adipocytes and referenced in hepatocytes as part of broader hGH‑fragment antilipogenic effects, potentially supporting increased whole‑body fat oxidation; however, direct liver signaling data for AOD9604 are limited in the cited excerpts.

Current limits of knowledge

• The initiating membrane receptor is not established. Evidence excludes the canonical GHR and points to secondary modulation of β3‑adrenergic signaling and lipid‑metabolic enzymes. Authors repeatedly describe the mechanism as complex and incompletely defined, warranting further receptor deconvolution and second‑messenger profiling.

Key evidence summary

Mechanism of action summary

• Receptor engagement: AOD9604/hGH177–191 does not bind or activate the GH receptor; the primary receptor target is unknown. Adipose tissues exhibit increased β3‑AR expression after treatment, which would sensitize cells to catecholamine‑driven cAMP/PKA signaling.
• Signaling: Data support a model in which the fragment amplifies lipolytic signaling in adipocytes via the cAMP/PKA axis (inferred from β3‑AR upregulation and HSL activation) and suppresses lipogenesis via ACC inhibition; DAG generation indicates concurrent remodeling of glycerolipid signaling.
• Molecular targets: HSL (activation) and ACC (inhibition) are the principal proximal enzymatic effectors observed; changes in FFA handling suggest enhanced oxidation pathways downstream of reduced malonyl‑CoA.
• Physiological effect: Increased lipid mobilization and fat oxidation with minimal glycemic perturbation, consistent with selective adipose‑directed actions rather than systemic GHR/IGF‑1 signaling.

Conclusion HGH Fragment 176–191 (AOD9604) promotes adipose lipolysis and suppresses lipogenesis through a mechanism independent of the GH receptor. The weight of evidence supports augmentation of β3‑adrenergic/cAMP‑PKA signaling with activation of HSL and inhibition of ACC, leading to increased fatty acid mobilization and oxidation. The precise initiating receptor for the fragment remains unassigned, and additional work is needed to resolve direct receptor binding, upstream second messengers, and tissue‑specific signaling in adipose and liver.

Therapeutic Applications#

HGH Fragment 176‑191 (AOD9604) has been developed primarily for obesity and metabolic health, based on adipose‑targeted lipolytic and antilipogenic actions observed in rodent models. Preclinical studies show reduced weight gain, increased fat oxidation, and shifts toward lipolysis without growth hormone–like diabetogenic effects. However, in humans, randomized controlled trials demonstrate an acceptable safety/tolerability profile without activation of the GH/IGF‑1 axis, but they do not show consistent or dose‑dependent weight‑loss efficacy over 12–24 weeks. Thus, the therapeutic concept is anti‑obesity/metabolic modulation, with strong preclinical signals but no robust clinical efficacy established to date.

Key evidence table

Preclinical applications and outcomes

• Anti‑obesity via adipose‑targeted lipid metabolism modulation. In ob/ob mice, 30‑day oral gavage of the fragment (AOD‑9401; 500 mg/kg/day) reduced the rate of weight gain by about 58% from day 16 onward (0.33 to 0.14 g/day; final 54.7 ± 1.8 g vs 52.5 ± 0.6 g). Ex vivo adipose assays showed increased lipolysis (glycerol release 0.63 → 1.02 mmol/g/h, P < 0.001) and reduced lipogenesis (~22% decrease; 4.23 → 3.31 pmol/mg/h, P < 0.0025), with plasma free fatty acids increased (1.06 → 1.38 mmol/L, P < 0.005). Acute IP dosing (250 mg/kg) transiently raised energy expenditure (+45%) and fat oxidation (+83%) within minutes.
• Obese mice fat oxidation and glycemia. With 14‑day chronic infusion in ob/ob mice (AOD9604 250 µg/kg/day), fat oxidation increased by ~216–230% vs baseline (P < 0.005/0.02) and circulating glycerol rose, indicating lipolysis. Importantly, AOD9604 did not raise plasma glucose or alter insulin, while comparator hGH induced hyperglycemia and a ~66–71% insulin decrease.
• Mechanistic studies in Zucker fatty rats showed the 177–191 fragment inhibits acetyl‑CoA carboxylase and increases hormone‑sensitive lipase, consistent with reduced lipogenesis and increased lipolysis; preliminary animal data reported >20% reduction in weight gain with 200 µg/kg/day IP for 18 days.

Clinical applications and outcomes

• Indication focus: obesity and metabolic health. Across six randomized, double‑blind, placebo‑controlled studies (≈893 adults), AOD9604 was evaluated in single‑dose IV (25–400 µg/kg), single‑dose oral (9–54 mg), short‑term multiple‑dose oral (7 days), and longer‑term daily dosing up to 24 weeks (0.25–1 mg/day; some studies used 5–30 mg/day for 12 weeks).
• Efficacy: Reviews and trial summaries indicate that a 12‑week randomized trial did not show dose‑dependent weight loss and that larger/longer studies failed to demonstrate robust clinical efficacy, including a study with intensive diet/exercise support that did not show additional weight loss vs placebo. Peer‑reviewed safety reports do not present consistent, statistically significant reductions in weight or fat mass compared with placebo.
• Safety and metabolic endpoints: Across studies, no clinically meaningful change in serum IGF‑1 vs placebo over 12 weeks (e.g., tabulated changes not different from placebo), no deterioration in glucose tolerance by OGTT, and no anti‑AOD9604 antibodies detected. Adverse events were similar to placebo overall; common events included headache and gastrointestinal symptoms, with higher GI events at the highest single oral dose (54 mg). Serious adverse events occurred at low frequency and were not attributed to the drug.

Interpretation

• Therapeutic applications: The fragment targets adipose lipid metabolism and has been investigated for obesity/weight management and metabolic health. Preclinical models demonstrate substantial increases in fat oxidation, shifts toward lipolysis, and reduced weight gain without GH receptor activation or diabetogenic effects.
• Clinical translation: Despite biological plausibility and safety, controlled trials to date have not established clinically meaningful weight‑loss efficacy. The absence of IGF‑1 elevation and lack of deterioration in glucose tolerance suggest a favorable safety/metabolic profile distinct from full‑length hGH.

Conclusion AOD9604/HGH Fragment 176‑191 shows anti‑obesity activity in rodent models, with quantitatively documented increases in fat oxidation, enhanced lipolysis, and reduced lipogenesis and weight gain. Human studies demonstrate good tolerability without GH‑axis activation or adverse effects on glucose tolerance, but do not show consistent, dose‑dependent or robust weight‑loss efficacy over 12–24 weeks. As a result, while the therapeutic concept is compelling, clinical effectiveness for obesity remains unproven in current evidence.

Research Evidence Quality#

Objective. To appraise the quality and extent of the evidence base for HGH fragment 176–191 (commonly referred to as AOD9604, previously AOD9401), and to identify key limitations, gaps, and criticisms.

Scope and nomenclature. AOD9604 is a modified C‑terminal fragment of human growth hormone corresponding roughly to residues 177–191; reports describe it as a hexadecapeptide and note an added N‑terminal tyrosine in some preparations (historically AOD9401). Preclinical documents describe cyclic/modified forms. Importantly, binding and proliferation assays indicate it does not activate the canonical hGH receptor (i.e., lacks GH‑like mitogenic activity).

Preclinical efficacy and proposed mechanisms. Across obese rodent models (ob/ob mice, Zucker rats), the 177–191 fragment and AOD9604 increase lipolysis and fat oxidation, reduce lipogenesis (e.g., via acetyl‑CoA carboxylase inhibition), and limit fat mass/weight gain during multi‑week dosing. Effects are stronger in obese versus lean animals and occur without the diabetogenic effects seen with full‑length hGH. Mechanistic observations include lack of competition at the hGH receptor and reports of β3‑adrenergic receptor upregulation in adipose tissue; the initiating target remains unidentified.

Human evidence: design, efficacy, safety. Human studies to date were primarily short‑term, randomized, double‑blind, placebo‑controlled trials conducted between 2001–2006 and focused on safety/tolerability, with limited reporting of weight‑loss efficacy endpoints. Aggregate enrollment across six trials was on the order of ~900 adults, largely with obesity. Reported outcomes show no clinically relevant change in IGF‑1, no deterioration in glucose control on OGTT, adverse events comparable to placebo, and minimal immunogenicity; isolated acute studies examined lipolysis markers. Consistent, statistically robust reductions in body weight or adiposity have not been demonstrated in the excerpts available.

Pharmacokinetics and nonclinical safety. Animal PK indicates rapid IV clearance (half‑life ~3 min) and detection after oral dosing in pigs, with tissue distribution to pancreas, thyroid, kidney cortex, and liver. Standard genotoxicity assays were negative, and long‑term toxicology in rodents/monkeys reported high NOAELs with low immunogenicity.

Regulatory/development status and criticisms. The development path shifted from a drug candidate toward positioning as a nutraceutical ingredient, with GRAS claims in secondary sources; there is no evidence in the retrieved texts of regulatory approval as an anti‑obesity drug. Common criticisms in the literature include: unclear molecular target/mechanism; reliance on small, short‑duration human studies emphasizing safety rather than efficacy; limited or unavailable primary efficacy data; ambiguous nomenclature/sequence variants; and a body of work concentrated in a limited set of developer‑affiliated groups.

Overall appraisal. The preclinical evidence base is moderate in size and internally consistent for lipolysis/fat‑oxidation in obese rodent models, with supportive mechanistic assays showing antilipogenic actions and no activation of the GH receptor. The human evidence base is limited in quality for efficacy: multiple randomized studies exist but are small, short, and primarily safety‑focused, and they have not established convincing weight‑loss or metabolic efficacy. Safety in the short‑term appears similar to placebo with neutral IGF‑1 and glucose effects. Regulatory progression to an approved anti‑obesity drug is not supported by the retrieved evidence, and nutraceutical positioning underscores the unresolved efficacy and mechanism. Larger, well‑powered, independently conducted RCTs with prespecified adiposity and metabolic endpoints, alongside target identification, are the principal evidence gaps.

Embedded summary table.

Evidence Gaps and Limitations#

The current evidence base for HGH Fragment 176-191 consists primarily of preclinical studies. Key limitations include:

• No completed randomized controlled trials in humans
• Most data derived from animal models, limiting direct translatability
• Publication bias may favor positive results
• Long-term safety data in humans is not available
• Optimal dosing for human applications has not been established

Key Research Findings#

Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment, published in Int J Obes Relat Metab Disord (Heffernan MA et al., 2001; PMID: 11673763):

AOD9604 reduced body weight gain in ob/ob mice; increased fat oxidation ~216-230% vs baseline; Did not induce hyperglycemia or reduce insulin secretion unlike full-length hGH

• AOD9604 reduced body weight gain in ob/ob mice; increased fat oxidation ~216-230% vs baseline
• Did not induce hyperglycemia or reduce insulin secretion unlike full-length hGH

The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice, published in Endocrinology (Heffernan MA et al., 2001; PMID: 11713213):

Both hGH and AOD9604 upregulated beta-3 adrenergic receptor expression in adipose tissue; Effects abolished in beta-3 AR knockout mice, confirming pathway importance

• Both hGH and AOD9604 upregulated beta-3 adrenergic receptor expression in adipose tissue
• Effects abolished in beta-3 AR knockout mice, confirming pathway importance

Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism, published in Am J Physiol Endocrinol Metab (Heffernan MA et al., 2000; PMID: 10950816):

Oral AOD-9401 (500 mg/kg/day for 30 days) reduced weight gain ~58% in ob/ob mice; Increased lipolysis and reduced lipogenesis in adipose tissue without affecting glucose or insulin

• Oral AOD-9401 (500 mg/kg/day for 30 days) reduced weight gain ~58% in ob/ob mice
• Increased lipolysis and reduced lipogenesis in adipose tissue without affecting glucose or insulin

Safety and tolerability of the hexadecapeptide AOD9604 in humans, published in J Endocrinol Metab (Stier H et al., 2013; DOI: ):

Across six RCTs (~893 adults), AOD9604 safety was indistinguishable from placebo; No effect on serum IGF-1 levels; no anti-AOD9604 antibodies detected; no impaired glucose tolerance

• Across six RCTs (~893 adults), AOD9604 safety was indistinguishable from placebo
• No effect on serum IGF-1 levels; no anti-AOD9604 antibodies detected; no impaired glucose tolerance

Safety and metabolism of AOD9604, a novel nutraceutical ingredient for improved metabolic health, published in J Endocrinol Metab (More MI and Kenley D, 2014; DOI: 10.14740/jem213w):

Preclinical NOAELs of >=100 mg/kg/day (rats) and >=50 mg/kg/day (monkeys); negative genotoxicity battery; Rapid IV clearance (t1/2 ~3 min); oral bioavailability demonstrated in pigs

• Preclinical NOAELs of >=100 mg/kg/day (rats) and >=50 mg/kg/day (monkeys); negative genotoxicity battery
• Rapid IV clearance (t1/2 ~3 min); oral bioavailability demonstrated in pigs

Related Reading#

• HGH Fragment 176-191 research studies and evidence
• HGH Fragment 176-191 dosing protocols
• HGH Fragment 176-191 side effects profile
• Ipamorelin research guide
• Sermorelin research guide